Agree. It's natural for investors to treat it as a success/failure decision when they are focused on the short-term. I just hope the FDA uses some common sense and treats this case similarly - there is a significant unmet need that very quickly needs to be addressed. And we have the drug that actually works - clear cut Phase 2 data. Don't delay us unnecessarily
Ann: Invex Granted Type C Meeting with FDA, page-113
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
